Indications

• Skin/Skin Structure Infections (SSI)
  • Methicillin-Sensitive Staphylococcus Aureus (MSSA) and Methicillin-Resistant Staphylcoccus Aureus (MRSA) (see Staphylococcus Aureus, [[Staphylococcus Aureus]])
  • Streptococcus Agalactiae (Group B Streptococcus) (see Streptococcus Agalactiae, [[Streptococcus Agalactiae]])
  • Streptococcus Anginosus Group (see Streptococcus Anginosus Group, [[Streptococcus Anginosus Group]])
    • Streptococcus Anginosus
    • Streptococcus Constellatus
    • Streptococcus Intermedius
  • Streptococcus Pyogenes (Group A β-Hemolytic Streptococcus) (see Streptococcus Pyogenes, [[Streptococcus Pyogenes]])

---

Pharmacology

• Glycopeptide Antibiotic

Metabolism

• xxxx

---

Administration

• IV: 1000 mg x1, then 500 mg one week later

Dose Adjustment

• Hepatic: cautious use in patients with Child-Pugh class B or C patients (inadequate safety data in this group of patients)
• Renal
  • CrCl <30 mL/min (Not on Hemodialysis): 750 mg x1, then 375 mg one week later

Pregnancy

• Inadequate Data

---

Adverse Effects

Allergic/Immunologic Adverse Effects

• Anaphylaxis (see Anaphylaxis, [[Anaphylaxis]])

Gastrointestinal Manifestations

• Clostridium Difficile Colitis (see Clostridium Difficile, [[Clostridium Difficile]])
• Diarrhea (see Diarrhea, [[Diarrhea]]): occurs in 4.4% of cases
• Elevated Liver Function Tests (LFT’s) (see xxxx, [[xxxx]]): elevated ALT
• Nausea (see Nausea and Vomiting, [[Nausea and Vomiting]]): occurs in 5% of cases

Neurologic Adverse Effects

• Headache (see Headache, [[Headache]]): occurs in 4.7% of cases

Other Adverse Effects

• xxx
• xxx
• xxx

---

References

• Dalvance® (dalbavancin) for injection Full Prescribing Information. Chicago, IL: Durata Therapeutics, Inc. 2014
• Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169-2179
• Economic burden of hospitalization with antibiotic treatment for ABSSSI in the United States: an analysis of the Premier Hospital Database. Presented at ISPOR 2012. Washington, D.C. June 2-6, 2012. (Poster PIN22)